R. E. Weir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
R. E. Weir has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Hazel M. Dockrell
Department of Infection Biology and Topical Diseases, London School of Hygiene & Tropical Medicine
6 shared publications G. F. Black
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
2 shared publicationsP. E. M. Fine
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
2 shared publicationsB Ngwira
1 shared publicationC R Butlin
The Leprosy Mission, Anandaban Leprosy Hospital, Kathmandu, Nepal
1 shared publicationC. R. Butlin
1 shared publication
Latest Publications
- Open Access
- 1 August 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (3) , 442-443
Reply
To the Editor —Ferreira et al. [1] compare cytokine responses induced by a second bacille Calmette-Guérin (BCG) vaccination in 7 adolescent boys with and 7 without helminthic or protozoan intestinal infections in Brazil. They report that, although the interferon (IFN)–γ responses to BCG antigens were initially similar and increased to a similar degree 30 days after BCG vaccination, IFN-γ production only increased further at 90 days after vaccination in the initially uninfected, untreated group. Interleukin (IL)–10 concentrations were significantly higher in the initially infected group at day 30, and Ferreira et al. suggest that the higher level of IL-10 may have been responsible for the reduced IFN-γ response at 90 days after vaccination. These relationships are complicated. IL-10 may play a role in the suppression of T cell and antibody responses, as observed following tetanus vaccination of subjects with Onchocerca infections [2]. The production of type 2 cytokines in response to helminthic infections is now well established, but there has been debate about whether the IFN-γ response to mycobacterial antigens is merely reduced [3] or whether a type 2 cytokine switch occurs [4] as a consequence of helminthic infection
- 1 August 2002
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (3) , 442-443
Open AccessReply
To the Editor —Ferreira et al. [1] compare cytokine responses induced by a second bacille Calmette-Guérin (BCG) vaccination in 7 adolescent boys with and 7 without helminthic or protozoan intestinal infections in Brazil. They report that, although the interferon (IFN)–γ responses to BCG antigens were initially similar and increased to a similar degree 30 days after BCG vaccination, IFN-γ production only increased further at 90 days after vaccination in the initially uninfected, untreated group. Interleukin (IL)–10 concentrations were significantly higher in the initially infected group at day 30, and Ferreira et al. suggest that the higher level of IL-10 may have been responsible for the reduced IFN-γ response at 90 days after vaccination. These relationships are complicated. IL-10 may play a role in the suppression of T cell and antibody responses, as observed following tetanus vaccination of subjects with Onchocerca infections [2]. The production of type 2 cytokines in response to helminthic infections is now well established, but there has been debate about whether the IFN-γ response to mycobacterial antigens is merely reduced [3] or whether a type 2 cytokine switch occurs [4] as a consequence of helminthic infection
- 1 July 2001
- Vol. 5 (7) , 664-72
Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi.
Rural northern Malawi, where vaccination with BCG Glaxo (1077) provides protection against leprosy but not against pulmonary tuberculosis. To evaluate the patterns of responsiveness to purified protein derivative of Mycobacterium tuberculosis (PPD) in terms of delayed type hypersensitivity (DTH) and interferon-gamma (IFN-gamma) production. IFN-gamma was measured in 6 day whole blood cultures diluted 1 in 10, stimulated with PPD RT48, and the results compared to the DTH response to PPD RT23. A total of 633 individuals aged 12 to 28 years, without prior BCG vaccination, were recruited. Overall, 63% of subjects made a positive IFN-gamma response (defined as >62 pg/ml), and 37% gave a DTH induration of >5 mm. A strong correlation between skin test and IFN-gamma responses was observed, although with interesting exceptions: 13/270 individuals with zero DTH showed IFN-gamma responses >500 pg/ml, and 7/53 individuals with >10 mm induration showed IFN-gamma responses < or = 62 pg/ml. The prevalence of skin test responsiveness increased with age, and was higher among older males than females; age-sex patterns were less clear for IFN-gamma production. The 6 day IFN-gamma response to PPD correlates well with Mantoux skin test induration. The discordant individuals may represent important subsets in terms of protective immunity and risk of clinical tuberculosis.
- 1 July 2001
- Vol. 5 (7) , 664-72
Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi.
Rural northern Malawi, where vaccination with BCG Glaxo (1077) provides protection against leprosy but not against pulmonary tuberculosis. To evaluate the patterns of responsiveness to purified protein derivative of Mycobacterium tuberculosis (PPD) in terms of delayed type hypersensitivity (DTH) and interferon-gamma (IFN-gamma) production. IFN-gamma was measured in 6 day whole blood cultures diluted 1 in 10, stimulated with PPD RT48, and the results compared to the DTH response to PPD RT23. A total of 633 individuals aged 12 to 28 years, without prior BCG vaccination, were recruited. Overall, 63% of subjects made a positive IFN-gamma response (defined as >62 pg/ml), and 37% gave a DTH induration of >5 mm. A strong correlation between skin test and IFN-gamma responses was observed, although with interesting exceptions: 13/270 individuals with zero DTH showed IFN-gamma responses >500 pg/ml, and 7/53 individuals with >10 mm induration showed IFN-gamma responses < or = 62 pg/ml. The prevalence of skin test responsiveness increased with age, and was higher among older males than females; age-sex patterns were less clear for IFN-gamma production. The 6 day IFN-gamma response to PPD correlates well with Mantoux skin test induration. The discordant individuals may represent important subsets in terms of protective immunity and risk of clinical tuberculosis.
- 1 January 2000
- Published by GN1 Sistemas e Publicacoes Ltd. in Leprosy Review
- Vol. 71, S60-2
Whole blood assays for interferon-γ: practicalities and potential for use as diagnostic tests in the field
Recent years have seen the introduction of a number of whole-blood assays, in which unseparated heparinized blood is stimulated with antigen either overnight or for as long as 6 days, and cytokine production is measured in the plasma or supernatant. These assays have potential for use in the field as immunodiagnostic assays, as they require only a small blood sample and basic laboratory facilities. Use of these assays in a large study of the immunological effects of BCG vaccination in Malawi has shown that the diluted blood, 6-day whole-blood assays is robust, and can be used to assess T-cell responses to both crude and recombinant antigens. If used with antigens specific to Mycobacterium leprae, these assays could be used to measure exposure of M. leprae within communities or populations, or to aid the early diagnosis of leprosy.
- 1 January 2000
- Published by GN1 Sistemas e Publicacoes Ltd. in Leprosy Review
- Vol. 71, S60-2
Whole blood assays for interferon-γ: practicalities and potential for use as diagnostic tests in the field
Recent years have seen the introduction of a number of whole-blood assays, in which unseparated heparinized blood is stimulated with antigen either overnight or for as long as 6 days, and cytokine production is measured in the plasma or supernatant. These assays have potential for use in the field as immunodiagnostic assays, as they require only a small blood sample and basic laboratory facilities. Use of these assays in a large study of the immunological effects of BCG vaccination in Malawi has shown that the diluted blood, 6-day whole-blood assays is robust, and can be used to assess T-cell responses to both crude and recombinant antigens. If used with antigens specific to Mycobacterium leprae, these assays could be used to measure exposure of M. leprae within communities or populations, or to aid the early diagnosis of leprosy.
- 1 May 1999
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 116 (2) , 263-269
Use of a whole blood assay to evaluatein vitroT cell responses to new leprosy skin test antigens in leprosy patients and healthy subjects
Development of an immunological tool to detect infection with Mycobacterium leprae would greatly benefit leprosy control programmes, as demonstrated by the contribution of the tuberculin test to tuberculosis control. In a new approach to develop a ‘tuberculin-like’ reagent for use in leprosy, two new fractions of M. leprae depleted of cross-reactive and immunomodulatory lipids— MLSA-LAM (cytosol-derived) and MLCwA (cell wall-derived)—have been produced in a form suitable for use as skin test reagents. T cell responses (interferon-gamma (IFN-γ) and lymphoproliferation) to these two new fractions were evaluated in a leprosy-endemic area of Nepal using a simple in vitro whole blood test. The two fractions were shown to be highly potent T cell antigens in subjects exposed to M. leprae—paucibacillary leprosy patients and household contacts. Responses to the fractions decreased towards the lepromatous pole of leprosy. Endemic control subjects also showed high responses to the fractions, indicating high exposure to M. leprae, or cross-reactive mycobacterial antigens, in this Nepali population. The new fractions, depleted of lipids and lipoarabinomannan (LAM) gave enhanced responses compared with a standard M. leprae sonicate. The cell wall fraction appeared a more potent antigen than the cytosol fraction, which may be due to the predominance of the 65-kD GroEL antigen in the cell wall. The whole blood assay proved a robust field tool and a useful way of evaluating such reagents prior to clinical trials.
- 1 May 1999
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 116 (2) , 263-269
Use of a whole blood assay to evaluatein vitroT cell responses to new leprosy skin test antigens in leprosy patients and healthy subjects
Development of an immunological tool to detect infection with Mycobacterium leprae would greatly benefit leprosy control programmes, as demonstrated by the contribution of the tuberculin test to tuberculosis control. In a new approach to develop a ‘tuberculin-like’ reagent for use in leprosy, two new fractions of M. leprae depleted of cross-reactive and immunomodulatory lipids— MLSA-LAM (cytosol-derived) and MLCwA (cell wall-derived)—have been produced in a form suitable for use as skin test reagents. T cell responses (interferon-gamma (IFN-γ) and lymphoproliferation) to these two new fractions were evaluated in a leprosy-endemic area of Nepal using a simple in vitro whole blood test. The two fractions were shown to be highly potent T cell antigens in subjects exposed to M. leprae—paucibacillary leprosy patients and household contacts. Responses to the fractions decreased towards the lepromatous pole of leprosy. Endemic control subjects also showed high responses to the fractions, indicating high exposure to M. leprae, or cross-reactive mycobacterial antigens, in this Nepali population. The new fractions, depleted of lipids and lipoarabinomannan (LAM) gave enhanced responses compared with a standard M. leprae sonicate. The cell wall fraction appeared a more potent antigen than the cytosol fraction, which may be due to the predominance of the 65-kD GroEL antigen in the cell wall. The whole blood assay proved a robust field tool and a useful way of evaluating such reagents prior to clinical trials.
- 1 June 1998
- Vol. 2 (6) , 441-2
Whole blood cytokine assays--a new generation of diagnostic tests for tuberculosis?
- 1 June 1998
- Vol. 2 (6) , 441-2
Whole blood cytokine assays--a new generation of diagnostic tests for tuberculosis?
- 1 January 1998
- Published by GN1 Sistemas e Publicacoes Ltd. in Leprosy Review
- Vol. 69 (3) , 279-93
Use of a whole blood assay to monitor the immune response to mycobacterial antigens in leprosy patients: a predictor for type 1 reaction onset?
Longitudinal studies are more appropriate than cross-sectional studies for investigating changes in the immune response to Mycobacterium leprae during leprosy, such as occur in type 1 (reversal) reactions. A test for predicting the onset of reactions in leprosy would greatly reduce disability associated with leprosy. Whole blood assays are appropriate for longitudinal studies of the in vitro T-cell response, as they are robust and reproducible, and require only a small volume of blood. Whole blood assays were used to assess the natural variation in the 'normal' T-cell response to mycobacterial antigens in healthy UK donors, and healthy Nepali donors, tested over 6 months. This was compared with variation in T-cell responses measured over 6 months in 22 leprosy patients in Nepal, including eight who developed type 1 reactions during this time. The in vitro T-cell response to M. leprae sonicate, M. tuberculosis PPD, the mitogen PHA, and (in the UK study) recombinant mycobacterial antigens (70 kD and 30/31 kD proteins) was measured by lymphoproliferation and interferon-gamma (IFN gamma) responses, and variation in responses over time in each subject calculated as a coefficient of variation (CV). The baseline high, low or non-responder status of the healthy UK donors remained stable. The magnitude of IFN gamma responses varied by mean CV ranging from 26% (to PPD) to 63% (to Mtb 70 kD); proliferation responses showed less variation, ranging from mean CV of 18% (to PHA) to 47% (to Mtb 70 kD). Response variation was independent of lymphocyte number in culture. Similar variation in lymphoproliferation responses to MLS, PPD and PHA was observed in the group of healthy Nepali subjects, and in Nepali leprosy patients who did not experience reactions during the study. Of the eight leprosy patients who developed type 1 reactions, four (two BT, one BB, one BL) showed significantly increased proliferation to MLS at the time of reaction (74-300% above baseline); four (one BB, two BL, one LL) remained low or non-responders to MLS throughout. An alternative marker of immune response--anti-phenolic glycolipid-1 (PGL-1) antibody titre--was not predictive of reaction onset in these patients. This study demonstrated that whole blood assays provide reproducible in vitro measurements that can be used to monitor changes in T-cell responses to M. leprae antigens; their practical use as a diagnostic marker of type 1 reaction onset is discussed.
- 1 January 1998
- Published by GN1 Sistemas e Publicacoes Ltd. in Leprosy Review
- Vol. 69 (3) , 279-93
Use of a whole blood assay to monitor the immune response to mycobacterial antigens in leprosy patients: a predictor for type 1 reaction onset?
Longitudinal studies are more appropriate than cross-sectional studies for investigating changes in the immune response to Mycobacterium leprae during leprosy, such as occur in type 1 (reversal) reactions. A test for predicting the onset of reactions in leprosy would greatly reduce disability associated with leprosy. Whole blood assays are appropriate for longitudinal studies of the in vitro T-cell response, as they are robust and reproducible, and require only a small volume of blood. Whole blood assays were used to assess the natural variation in the 'normal' T-cell response to mycobacterial antigens in healthy UK donors, and healthy Nepali donors, tested over 6 months. This was compared with variation in T-cell responses measured over 6 months in 22 leprosy patients in Nepal, including eight who developed type 1 reactions during this time. The in vitro T-cell response to M. leprae sonicate, M. tuberculosis PPD, the mitogen PHA, and (in the UK study) recombinant mycobacterial antigens (70 kD and 30/31 kD proteins) was measured by lymphoproliferation and interferon-gamma (IFN gamma) responses, and variation in responses over time in each subject calculated as a coefficient of variation (CV). The baseline high, low or non-responder status of the healthy UK donors remained stable. The magnitude of IFN gamma responses varied by mean CV ranging from 26% (to PPD) to 63% (to Mtb 70 kD); proliferation responses showed less variation, ranging from mean CV of 18% (to PHA) to 47% (to Mtb 70 kD). Response variation was independent of lymphocyte number in culture. Similar variation in lymphoproliferation responses to MLS, PPD and PHA was observed in the group of healthy Nepali subjects, and in Nepali leprosy patients who did not experience reactions during the study. Of the eight leprosy patients who developed type 1 reactions, four (two BT, one BB, one BL) showed significantly increased proliferation to MLS at the time of reaction (74-300% above baseline); four (one BB, two BL, one LL) remained low or non-responders to MLS throughout. An alternative marker of immune response--anti-phenolic glycolipid-1 (PGL-1) antibody titre--was not predictive of reaction onset in these patients. This study demonstrated that whole blood assays provide reproducible in vitro measurements that can be used to monitor changes in T-cell responses to M. leprae antigens; their practical use as a diagnostic marker of type 1 reaction onset is discussed.